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patients. The plans allow geometrical ad-hoc adaptation to large 
interfractional deformations of patient geometry.  
Materials and Methods: Patients with intermediate or high-risk 
prostate cancer are normally treated using VMAT technique with 
Simultaneously Integrated Boost at our department. The CTV is 
defined as the prostate and the base of seminal vesicles. The Boost 
(PTV) is obtained by expanding the CTV by 5 (10) mm. Prescription 
doses to PTV and Boost are respectively 60.1 and 74 Gy given in 33 
fractions. 
Our method of IMAT for prostate cancer uses three arcs. We analyze 
the geometry of the structures of interest (PTV and rectum), and 
generate segments to deliver three fluence steps: conformal (Step 0, 
first arc), sparing the rectum (Step 1, second arc), and narrow 
segments compensating for the underdosage in the PTV due to rectum 
sparing (Step 2, third arc). The width of Step 2 segments is calculated 
for every MLC leaf pair based on the PTV and rectum geometry in the 
corresponding CT layer to have best dose homogeneity. The segments 
are then fed into the DMPO engine of Pinnacle for weight optimization 
and fine-tuning of the form. We call this method '2-Step IMAT'. 2-Step 
IMAT and reference VMAT plans show highly equivalent target 
coverage, rectum sparing, and dosimetric quality, with 2-Step IMAT 
taking on average 230 sec to deliver vs 100 sec for VMAT. 
We adapt 2-Step IMAT plans to changed geometry preserving the 
number of Monitor Units (MU) calculated for each segment at initial 
geometry. The leaves of Step 0 segments follow the edges of the PTV 
in Beam Eye View to keep PTV conformally irradiated. The leaves of 
Step 1 segments follow the edges of the rectum to keep it spared. For 
Step 2 segments, the opening of each leaf pair is adapted to the 
geometry change in the corresponding CT layer to have best dose 
homogeneity under the condition of MU preservation.  
Results: Four adaptation cases have been considered. The ones having 
best and worst improvement of target coverage between relocated 
and adapted plan are shown in Fig.1 a,b and Tab. 1. The target 
coverage is measured by SD index which sums up violations of dose 
requirements for Boost and PTV-Boost:  
 
To characterize rectum sparing we measure absolute rectum volumes 
cut out by 95%-, 80%-, and 50%-isodose.  
 
 
Fig.1. DVHs for the adaptation cases with the best (a) and the worst 
(b) target coverage: dotted – relocation, thin – new optimization, 
thick – adaptation. 
 Tab.1. Evaluation for Fig.1. 
 
Conclusions: The 2-Step IMAT method delivers prostate plans 
equivalent to the reference VMAT plans. On the expense of 2-3 longer 
delivery time 2-Step IMAT plans offer the possibility to adapt to large 
interfractional changes of patient geometry. 
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Purpose/Objective: Concurrent chemoradiotherapy has been a 
standard treatment for good performance status patients with 
unresectable stage III non–small cell lung cancer (NSCLC). However, 
the toxicities were not neglected. To evaluate pemetrexed in 
combination with cisplatin in these patients, a randomized phase III 
study of concurrent cisplatin with pemtrexed or vinorelbine and late 
course accelerated hyperfractionated radiotherapy (LCAHRT) was 
performed. 
Materials and Methods: Total of 86 patients were randomly assigned 
to two concurrent regimens beforeMarch 2012. Arm1 included 
cisplatin at 25 mg/m2 on days 1-3, 22-24 and vinorelbine at 25 mg/m2 
on days 1,8 and 22,29 with concurrent late course accelerated 
hyperfractionated radiotherapy. Arm 2 used cisplatin at 25 mg/m2 on 
days 1-3, 22-24 and pemtrexed at 500 mg/m2 on days 1 and 22 with 
the same radiotherapy protocol. The primary endpoint was overall 
survival (OS), and secondary endpoints included toxicities. Kaplan–
Meier analyses were used to assess survival, and toxic effects were 
examined using the Pearson Chi-Square test. All statistical tests were 
two-sided. 
Results: 84 patients were analyzed for 2 patients in arm 1 were not 
finished treatment according to the protocol. The mean radiation 
dose in arms 1–2 was 66.2±7.5 Gy and 67.9±7.4 Gy. 76 patients used 2 
cycle concomitant chemotherapy, 4 cases 3 cycles, and 4 ones 1 cycle 
(3 in arm 1 and 1 in arm 2). Median OS were 23 and 25 months for 
arms 1 and 2, respectively (p=0.224). Concerning toxicities of grade 2 
or more in the arms 1 and 2, the white blood cell was 32/41 and 
20/43 (p=0.003), esophagitis 14/41 and 10/43 (p=0.269), pneumonitis 
8/41 and 6/43 (p=0.494), vomiting 13/41 and 9/43 (p=0.261), 
hemotoblatin 8/41 and 5/43 (p=0.318), platelet 9/41 and 5/43 
(p=0.204), respectively. 
Conclusions: Concurrent cisplatin with pemtrexed and LCAHRT was as 
effective as with vinorelbine for unresectable stage III non–small cell 
lung cancer, however, the treatment compatibility was better.  
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Purpose/Objective: To evaluate patterns-of-care and patterns-of-
outcome after stereotactic body radiotherapy (SBRT) for stage I non-
small cell lung cancer (NSCLC). 
Materials and Methods: The working group 'Extracranial Stereotactic 
Radiotherapy' of the German Society of Radiation Oncology (DEGRO) 
performed a multi-center analysis of practice and outcome after SBRT 
for stage I NSCLC: 16 German and Austrian centers with experience in 
pulmonary SBRT were asked for participation. 
Results: Data of 582 patients treated in 13 institutions between 1998-
2011 were collected; all but one institution were academic hospitals. 
In 2010, the last full year covered in this analysis, 95 patients in total 
were treated with SBRT. The median number of patients per 
institution was 39 (range 8-110) and the median number of patients 
per institution and year was 5 (range 1-29). Median patient age was 72 
years (range 31-92) and median pre-treatment FEV1 was 58% (range 
16-129%). Median maximum tumor diameter was 2.5cm. NSCLC was 
biopsy confirmed in 84.5% of the patients. A time trend to more 
advanced radiotherapy technologies (nodal staging using FDG-PET, 
advanced type B dose calculation algorithm, in-room image guidance) 
was observed. The PTV encompassing dose was increased continuously 
and reached a plateau of 94Gy±26Gy BED (α/β=10Gy) on average in 
2006-2011. Patient characteristics (age, performance status, 
pulmonary function) remained stable over time. Inter-institutional 
variability was substantial in all treatment characteristics. In contrast, 
there was no inter-institutional variability in pre-treatment patient 
age and pulmonary function. After average follow-up of 21 months, 
three-years freedom from distant recurrence (FFDR), regional 
recurrence (FFRR) and local progression (FFLP) were 63.4%, 75.4% and 
79.6% for all 582 patients, respectively. Three-years overall survival 
(OS) was 47.1%. The biological effective dose (BED) was the most 
significant factor influencing all patterns of failure and OS in uni- and 
multivariate analysis. After ≥106Gy BED as planning target volume 
encompassing dose (n=164), three-years FFDR, FFRC, and FFLP were 
74.8%, 90.4% and 92.5%, respectively; three-years OS was 62.2%. The 
figure below shows OS depending on stage and irradiation dose. 
 
No evidence for a learning curve of improved results with larger SBRT 
experience or practice was observed. Radiation induced pneumonitis 
grade ≥2 was observed in 7.4% of the patients and grade 5 
pneumonitis was documented in only two patients.Thirty day 
mortality after SBRT was 0.5% (n=3). 
Conclusions: After irradiation doses ≥106Gy BED, favorable and 
consistent outcome after SBRT for stage I NSCLC was observed in this 
multi-institutional analysis despite substantial time-trends and inter-
institutional variability in the methodology of SBRT.  
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Purpose/Objective: Despite the increasing number of decision making 
tools, many are not used in daily clinical practice. Implementation 
might be stimulated if it is obvious that models can offer valuable 
extra information. We previously reported that prediction models 
outperformed physicians' predictions based on chart review. However, 
physically seeing a patient provides the doctor with extra information. 
The purpose of this prospective study was to compare predictions 
based on statistical models to predictions made by the physicians 
after they had seen the patient.  
Materials and Methods: Based on the performance of already pub-
lished and validated prediction models for lung cancer, we hypothe-
sized that these models would outperform the doctors prediction by 
at least 0.1 in Area Under the Curve (AUC) of the ReceiverOperating 
Characteristic (ROC). The required sample size for the primary out-
come, 2-yr survival, was 128 patients. Model predictions were ob-
tained and experienced radiation oncologists were asked to predict 2 
year survival,dyspnea (≥grade III) and dysphagia (≥grade III) at two 
time points: 1) after they had seen the patient for the first visit, and 
2) after the treatment plan was made. For survival prediction NSCLC 
patients,stage I-IIIB, were included;for dyspnea and dysphagia both 
NSCLC and SCLC were included. All patients were treated with radio-
therapy with or without chemotherapy, did not have surgery,no other 
tumor<5 years ago, and no distant metastasis. We compared the 
performance of the models to the doctors' in terms of AUC. To gain 
more insight in the benefit of using predictions in clinical practice we 
analysed the positive (PPV) and negative predictive value (NPV) for all 
possible cut-off values of the probabilities. In addition, Kaplan Meier 
curves based on TNMstage were made. 
 
 
Results:  At time point 1 the doctors predicted outcome for 121, 139 
and 146 patients (2-yr survival, dyspnea and dysphagia respectively). 
The AUCs of the doctors were 0.56, 0.59 and 0.52,while the models 
yielded AUCs of 0.71, 0.76 and 0.72, with p-values for difference in 
AUC of 0.02, 0.06 and 0.03 respectively. The Kaplan Meier curves 
based on TNM stage could not identify survival risk groups (p=0.33). 
Predictions at time point 2 were only available for 35,39 and 41 
patients (survival, dyspnea and dysphagia). Results were in line with 
those at time point 1. The PPVs of the models were generally higher, 
while the NPVs of doctors and models were comparable, indicating 
that the models could better identify high risk patients. 
Conclusions: Prediction models for lung cancer patients substantially 
outperformed the physicians' prediction for all outcomes. The differ-
ence between doctors and models did not decrease after the doctors 
had seen the treatment planning. The models were especially superior 
in identifying high risk patients and should therefore be implemented 
in clinical practice to guide decisions. 
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Purpose/Objective: Radiation induced toxicity is an important issue in 
head and neck cancer patients. With the introduction of IMRT into 
daily practice we are able to minimize doses to organs-at-risk while 
maintaining adequate tumor coverage. However, the commonly used 
elective nodal site doses might result in neck fibrosis and dysphagia. 
The goal of this randomized, multicenter trial was to investigate 
whether a reduction of the dose to the elective nodal sites and off-
target regions of the swallowing apparatus delivered by IMRT would 
result in a reduction of both acute and late side effects without 
compromising tumor control.  
Materials and Methods: Two-hundred patients with histologically 
proven head and neck squamous cell carcinoma were randomly 
assigned to the standard and experimental arm. In the standard arm 
the elective nodal volumes (PTVelective) were irradiated up to an 
equivalent dose of 50Gy in 2 Gy fractions. In the experimental arm an 
equivalent dose of 40Gy in 2 Gy fractions was delivered to the nodal 
volumes and the dose to the swallowing apparatus was kept as low as 
reasonably possible without compromising coverage of the therapeutic 
PTV (PTVther). Toxicity was recorded using CTCAE v3.0 weekly during 
